RLMD

RELMADA THERAPEUTICS, INC.

Healthcare · Biotechnology

$155.14 sample

+0.97 (+0.63%) 1D

Market cap

$749.4B

Price as of

2026-10-15

Latest filing

8-K · 2026-10-02

Alerts

8

Price$155.14 +1.37% 3M daily closessample

162.09151.17

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 12INSInsider sell: EVP, Operations
Oct 02SECForm 144 filed
Sep 29SEC8-K filed: material event
Sep 18INSInsider sell: Chief Financial Officer
Sep 14SECForm 144 filed
Sep 03INSInsider buy: 10% owner
Aug 26SEC8-K filed: material event
Aug 20INSInsider buy: Chief Executive Officer

Sign up to see the real RLMD record →

Company facts

SEC EDGAR registration

Name: RELMADA THERAPEUTICS, INC.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: +19sample, -100 to +100
Reporting currency: USD

Who is positioning in RLMD

sample

Insiders: 17 insider transactions over 90 days, net selling, $386.9M
Congress: 1 members traded over 90 days
Institutions · 13F: 30 funds hold $11.6B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$39.6B +18.1% y/y

Q4 2024Q3 2026

Inventory$24.3B +22.9% y/y

Q4 2024Q3 2026

Accounts receivable$17.0B +6.8% y/y

Q4 2024Q3 2026

Total debt$46.9B +12.4% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $310.0B +15.4% 3M
Sample peer B: $490.5B +14.3% 3M
Sample peer C: $723.6B -9.4% 3M
Sample peer D: $308.0B +10.5% 3M
Sample peer E: $655.5B +9.0% 3M